Abbott Laboratories (NYSE:ABT) finished Wednesday with a subtraction of -$1.66 to close at $100.65, a downside of -1.62 percent. An average of 5,257,820 shares of common stock have been traded in the last five days. There was a fall of -$5.13 in the past week, and it reached a new high 17 times over the past 12 months. The last 20 days have seen an average of 5,169,725 shares traded, while the 50-day average volume stands at 4,526,814.
ABT stock has decreased by -6.33% in the last month. The company shares reached their 1-month lowest point of $100.62 on 09/21/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $101.21 and a high of $142.60 in 52 weeks. It has reached a new high 1 time so far this year and lost -28.49% or -$40.09 in price. In spite of this, the price is down -29.42% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
14 days have passed since Abbott Laboratories (ABT) last reported insider trading activity. MANNING JOSEPH J, who is EXECUTIVE VICE PRESIDENT, most recently acquired $23,008 shares at $107.00 per share on Sep 08. In this transaction, the insider spent $2,461,856. CHAIRMAN AND CEO, Ford Robert B, disposed of 102,425 shares at a price of $105.10 on Aug 25. The insider now owns more than $10,765,154 worth of shares. Prior to that, EXECUTIVE VICE PRESIDENT MANNING JOSEPH J went on to Sale 26,898 shares at $105.03 each on Aug 25. An amount of $2,825,088 was transacted.
Abbott Laboratories (ABT) has a trailing price-to-earnings (P/E) ratio of 20.92. The stock’s beta is 0.71. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.91, the price-to-book (PB) ratio at 4.84, and the price-to-cash flow ratio at 34.18.
The company has a payout ratio of 38.00%. The company’s most recent quarterly dividend payment was $0.47 a share, without any change from last year. Its latest increase dividend $0.02 reported on Friday December 10 2021.
The quick ratio of Abbott Laboratories for the three months ended June 29 was 1.50, and the current ratio was 2.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.46 and a total debt to equity ratio of 0.46 for the quarter ending June 29. Its gross profit as reported stood at $24.54 billion compared to revenue of $43.08 billion.
For the three-month period that ended June 29, Abbott Laboratories had $353.0 million in cash and short-term investments compared to $16.75 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $2.02 billion in the quarter, while revenues of $2.45 billion were grew 41.08%. The analyst consensus anticipated Abbott Laboratories’s latest quarter earnings to come in at $1.13 per share, but it turned out to be $1.43, a 26.50% surprise. For the quarter, EBITDA amounted to $3.2 billion. Shareholders own equity worth $1.75 billion.
From a technical analysis perspective, let’s take a brief look at Abbott Laboratories (ABT) price momentum. RSI 9-day as of the close on 21 September was 29.96%, suggesting the stock is oversold, with historical volatility in this time frame at 20.26%.
As of today, ABT’s price is $103.22 -4.85% or -$5.13 from its 5-day moving average. ABT is currently trading -5.06% lower than its 20-day SMA and -14.71% lower than its 100-day SMA. However, the stock’s current price level is -7.06% below the SMA50 and -22.74% below the SMA200.
The stochastic %K and %D were 13.96% and 24.86%, respectively, and the average true range (ATR) was 2.37. With the 14-day stochastic at 0.33% and the average true range at 2.29, the RSI (14) stands at 35.08%. The stock has reached -2.71 on the 9-day MACD Oscillator while the 14-day reading was at -2.45.
Wolfe Research launched coverage on Abbott Laboratories (NYSE: ABT) in its analyst report released on July 06, 2022. The firm assigned the stock an Underperform rating.